Multiple Rising Dose Study of MK-6194 in Participants With Atopic Dermatitis (MK-6194-008)

The main inclusion and exclusion criteria include but are not limited to the following:

Inclusion Criteria:

• Clinical diagnosis of atopic dermatitis for at least 6 months prior to the Screeningvisit.

• Atopic dermatitis is of at least moderate severity.

• History of inadequate response to a stable (≥1 month) regimen of medium to highpotency topical corticosteroids or calcineurin inhibitors as treatment for atopicdermatitis within 6 months before the screening visit.

• Body Mass Index (BMI) ≥18 and ≤38 kg/m2 at the screening visit.

Exclusion Criteria:

• Concurrent significant skin disease other than atopic dermatitis (such as psoriasis)or a concurrent clinically significant disease.

• Significant organ dysfunction that is unstable or inadequately treated within 6months prior to Screening.

• History of cancer (malignancy), with the exceptions: of adequately treatednonmelanomatous skin carcinoma or carcinoma in situ of the cervix or; othermalignancies that have been successfully treated with appropriate follow up.

• History of myocardial infarction, congestive heart failure, uncontrolledarrhythmias, cardiac revascularization, stroke, uncontrolled hypertension, oruncontrolled diabetes within 6 months of Screening.

• History of organ or tissue allograft.

• History of symptomatic herpes zoster within 16 weeks of randomization, or anyhistory of disseminated herpes simplex, disseminated herpes zoster, ophthalmiczoster, or central nervous system (CNS) zoster.

• Major surgery within 3 months prior to the screening visit or has a major surgeryplanned during the study.

• Received a live or attenuated virus vaccine within 4 weeks prior to the Screeningvisit or intends to receive live or attenuated virus vaccination during the courseof the study and for 12 weeks after the last dose of study drug.

• Currently receiving any chronic systemic (oral or intravenous) anti-infectivetherapy for chronic infection (such as pneumocystis, cytomegalovirus, herpes zoster,or atypical mycobacteria).